Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

13.94
+0.05000.36%
Volume:692.45K
Turnover:9.69M
Market Cap:1.91B
PE:-2.71
High:14.25
Open:13.89
Low:13.43
Close:13.89
Loading ...

Arrowhead Pharmaceuticals: Strategic Licensing Deal and Upcoming Drug Launch Drive Buy Rating

TIPRANKS
·
11 Feb

Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Feb

Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines -- Shares Down After Hours

MT Newswires Live
·
11 Feb

Arrowhead Pharma Q1 2025 GAAP EPS $(1.39) Misses $(0.63) Estimate, Sales $2.50M Miss $65.47M Estimate

Benzinga
·
11 Feb

Arrowhead Research: Fiscal Q1 Earnings Snapshot

Associated Press Finance
·
11 Feb

Arrowhead reports Q1 EPS ($1.39), consensus (72c)

TIPRANKS
·
11 Feb

Arrowhead Closes Licensing, Collaboration Agreement With Sarepta

MT Newswires Live
·
10 Feb

Arrowhead to receives $500M upfront in licensing pact with Sarepta

TIPRANKS
·
10 Feb

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement With Sarepta Therapeutics

THOMSON REUTERS
·
10 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Feb

Genelux Names Matthew Pulisic as CFO

MT Newswires Live
·
03 Feb

Genelux Brings in Arrowhead Pharmaceuticals Exec as New Finance Chief

Dow Jones
·
03 Feb

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Jan

BRIEF-S&P Dow Jones Indices Says Arrowhead Pharmaceuticals Will Replace Barnes Group Inc. In S&P Smallcap 600

Reuters
·
23 Jan

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

PR Newswire
·
23 Jan

Guidewire to replace Arrowhead in S&P 400 index at open on 1/27

TIPRANKS
·
23 Jan

S&P Dow Jones Indices: Arrowhead Pharmaceuticals Will Replace Barnes Group Inc. in S&P Smallcap 600

THOMSON REUTERS
·
23 Jan

Arrowhead Pharmaceuticals' New Drug Application for Plozasiran Accepted by FDA

MT Newswires Live
·
18 Jan

FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment

Dow Jones
·
18 Jan

Arrowhead says FDA accepts NDA for investigational plozasiran

TIPRANKS
·
18 Jan